

**Supplementary table 1.**

**Summary of melanoma patients, MAF and DF cultures, and their involvement in individual experiments**

Patient ID	Gender	Age	Diagnosis, clinical grading	Therapy	Isolated fibroblasts	Melanoma / origin of fibroblasts	Fig.1	Fig.2a	Fig.2b	Fig.2c	Fig.2d	Fig.3a	Fig.3b	Fig.3c	Fig.3d	Fig.4	Fig.5	Fig.6 a-d	Fig.6e	Fig.7
5	female	79	pT3N2cM0 SSM‡	CDDP§, vemurafenib, DTIC†	DF, MAF	metastatic, cutaneous	x	x	x		x	x	x			x	x			
15	male	71	MM	Interferon alpha-2b	DF, MAF	metastatic, cutaneous	x	x	x	x	x	x	x	x	x	x	x	x	x	x
19	male	57	pT2a SSM	0	DF, MAF	primary, cutaneous	x	x	x	x	x	x	x	x		x	x	x	x	x
22	male	74	pT4b MM	0	DF, MAF	primary, cutaneous	x	x	x	x	x	x	x	x	x	x	x	x	x	x
23	male	69	pT4b MM	0	DF, MAF	primary, cutaneous	x	x	x	x		x	x	x	x		x	x	x	
35	male	76	pT3b MM	0	DF, MAF	metastatic, cutaneous	x	x	x		x	x	x	x	x	x	x	x	x	
41	male	43	MM	Interferon alpha-2b	DF, MAF	metastatic, cutaneous	x			x		x	x			x			x	x
48	male	71	pT3b SSM	0	DF, MAF	primary, cutaneous	x			x		x	x						x	
55	male	58	pT4b non-classifiable MM	0	DF, MAF	primary, cutaneous	x			x		x	x						x	

† DTIC: dacarbazine; § CDDP: cisplatin; ‡ SSM: superficial spreading melanoma

Melanoma-associated fibroblasts impair CD8+ T cell function and modify expression of immune checkpoint regulators via increased arginase activity

Barbara Érsek<sup>1,2\*</sup>, Pálma Silló<sup>3\*</sup>, Ugur Cakir<sup>3</sup>, Viktor Molnár<sup>4</sup>, András Bencsik<sup>1</sup>, Balázs Mayer<sup>3</sup>, Eva Mezey<sup>5</sup>, Sarolta Kárpáti<sup>3</sup>, Zoltán Pósi<sup>§</sup> and Krisztián Németh<sup>3§</sup>

Corresponding author:

Zoltán Pósi

Department of Genetics, Cell and Immunobiology, Semmelweis University

4 Nagyvarad ter, VII/709, Budapest, H-1089, Hungary

Phone: +36-1-210-2930 Ext. 56435

Fax: +36-1-303-6968

E-mail: [pos.zoltan@med.semmelweis-univ.hu](mailto:pos.zoltan@med.semmelweis-univ.hu)